Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States, Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of articular cartilage defects in the knee and Epicel® (cultured epidermal autografts), a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area. Aastrom is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
Developing multicellular treatments—with integrity
To fulfill Aastrom’s mission of helping people with severe diseases and conditions realize the promise of patient-specific cell therapy, we hold fast to our values, always using rigorous scientific methods to test hypotheses and evaluate our products’ potential. Personal integrity and accountability to our stakeholders are the foundations of our work, and we seek to practice transparency and openness in our dealings with each other, our patients, and our investors.